BioCryst director granted shares and options
BioCryst Pharmaceuticals director Jon P. Stonehouse reported routine equity compensation grants.
Rhea-AI Filing Summary
BioCryst Pharmaceuticals director Jon P. Stonehouse reported routine equity compensation grants. He received 15,294 shares of Common Stock as a grant, increasing his direct holdings to 1,339,775 shares. These shares were granted at no cash cost as part of his non-employee director compensation.
He was also granted an Automatic Stock Option for 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. Footnotes explain these are automatic non-employee director grants of Restricted Stock Units and stock options under BioCryst’s Director Compensation Policy. Two family irrevocable trusts associated with his wife each report indirect holdings of 40,000 Common Stock shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 48,834 shares
Grant/Award
4 txns
Insider
Stonehouse Jon P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Automatic Stock Option Grant | 33,540 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 15,294 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Automatic Stock Option Grant — 33,540 contracts (Direct);
Common Stock — 1,339,775 shares (Direct);
Common Stock — 40,000 shares (Indirect, By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust);
Common Stock — 40,000 shares (Indirect, By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust)
Footnotes (2)
- F1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
- F2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Key Figures
RSU grant: 15,294 shares
Direct holdings after grant: 1,339,775 shares
Stock option grant size: 33,540 options
+4 more
7 metrics
RSU grant
15,294 shares
Automatic non-employee director grant of Restricted Stock Units
Direct holdings after grant
1,339,775 shares
Common Stock directly held after RSU grant
Stock option grant size
33,540 options
Automatic Stock Option Grant for Common Stock
Option exercise price
$8.50 per share
Exercise price for Automatic Stock Option Grant
Option expiration
June 11, 2036
Expiration date of Automatic Stock Option Grant
Indirect trust holding (Samuel trust)
40,000 shares
Common Stock held by Samuel Stonehouse Irrevocable Trust
Indirect trust holding (Caroline trust)
40,000 shares
Common Stock held by Caroline Stonehouse Irrevocable Trust
Key Terms
Restricted Stock Units, Director Compensation Policy, Automatic Stock Option Grant, Irrevocable Trust
4 terms
Restricted Stock Units financial
"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Director Compensation Policy financial
"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy")"
Automatic Stock Option Grant financial
"security_title": "Automatic Stock Option Grant""
Irrevocable Trust financial
"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did BioCryst (BCRX) report for Jon P. Stonehouse?
BioCryst reported that director Jon P. Stonehouse received equity compensation grants. He was awarded 15,294 shares of Common Stock and an Automatic Stock Option for 33,540 shares, all under the company’s non-employee Director Compensation Policy.
What are the terms of Jon P. Stonehouse’s new stock options in BioCryst (BCRX)?
Stonehouse received an Automatic Stock Option covering 33,540 shares of BioCryst Common Stock at an exercise price of $8.50 per share. The option expires on June 11, 2036 and was granted under the company’s Director Compensation Policy.
How do the Restricted Stock Units granted to Jon P. Stonehouse in BioCryst (BCRX) vest?
The 15,294 Restricted Stock Units granted to Stonehouse will vest on the first anniversary of the grant date. This vesting schedule is set by BioCryst’s Non-Employee Director Compensation Policy, which governs automatic equity awards to non-employee directors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
